DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 39.1% from a year ago
Total equity stood at $47.24M at the end of Q1 FY2026, up 39.1% from a year earlier and down 15.8% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.
Context
- Total equity amounted to 89.0% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +39.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 56.11M USD
- Year-over-year change
- +37.8%
- 4-year CAGR
- +6.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 56.11M | +37.8% |
| FY2024 | 2024-12-31 | 40.72M | -20.2% |
| FY2023 | 2023-12-31 | 51.06M | +60.4% |
| FY2022 | 2022-12-31 | 31.83M | -27.7% |
| FY2021 | 2021-12-31 | 44.02M | — |
Total Equity vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total equity of $47.24M is the 5th highest of the 7 companies compared; the peer median is $302.4M.
- Its year-over-year change of +39.1% is the 2nd highest of 7, against a peer median of +14.2%.
- Total equity amounts to 89.0% of total assets for DMAC, versus a peer median of 76.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $835.18M | -18.7% | -0.9% | 72.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $379.12M | +21.1% | — | 95.3% |
| Mar 2026 | $341.7M | +17.0% | +51.8% | 81.4% | |
| Mar 2026 | $263.1M | -28.9% | -15.9% | 89.9% | |
| Mar 2026 | $47.24M | +39.1% | +20.8% | 89.0% | |
| Mar 2026 | $37.7M | +234.5% | — | 58.5% | |
| Mar 2026 | $27.38M | +11.4% | +84.1% | 7.6% | |
| Peer median (excluding DMAC) | $302.4M | +14.2% | +25.4% | 76.8% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.